These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26312105)

  • 1. Effect of Adalimumab on Work Ability Assessed in Rheumatoid Arthritis Disease Patients in Saudi Arabia (AWARDS).
    Hussain W; Janoudi N; Noorwali A; Omran N; Baamer M; Assiry el H; Alrayes H; Alosaimi H; Ibrahim A; Gohary S; Mignuet J; Almoallim H
    Open Rheumatol J; 2015; 9():46-50. PubMed ID: 26312105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
    Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
    Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study.
    Behrens F; Tony HP; Koehm M; Schwaneck EC; Gnann H; Greger G; Burkhardt H; Schmalzing M
    Clin Rheumatol; 2020 Sep; 39(9):2583-2592. PubMed ID: 32206973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
    Takeuchi T; Nakajima R; Komatsu S; Yamazaki K; Nakamura T; Agata N; Igarashi A; Tango T; Tanaka Y
    Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability - Saudi Rheumatoid Arthritis Registry.
    Almoallim H; Janoudi N; Alokaily F; Alzahrani Z; Algohary S; Alosaimi H; Attar S
    Open Access Rheumatol; 2019; 11():89-95. PubMed ID: 31118842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
    Emery P; Smolen JS; Ganguli A; Meerwein S; Bao Y; Kupper H; Chen N; Kavanaugh A
    Rheumatology (Oxford); 2016 Aug; 55(8):1458-65. PubMed ID: 27114561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database.
    Sakai R; Tanaka E; Inoue E; Sato M; Tanaka M; Ikari K; Yamanaka H; Harigai M
    Mod Rheumatol; 2023 Aug; 33(5):899-905. PubMed ID: 36094815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia.
    Janoudi N; Omran N; Hussain W; Al-Osaimi H; Baamer M; Siddiqui MI; Fathaldin O; Almoallim H
    Open Access Rheumatol; 2017; 9():181-184. PubMed ID: 29089788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Tektonidou MG; Katsifis G; Georgountzos A; Theodoridou A; Koukli EM; Kandili A; Giokic-Kakavouli G; Karatsourakis TD
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20949088. PubMed ID: 33062067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA.
    Bansback N; Zhang W; Walsh D; Kiely P; Williams R; Guh D; Anis A; Young A
    Rheumatology (Oxford); 2012 Feb; 51(2):375-84. PubMed ID: 22179728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.